Japan Lung Cancer Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Type (Non-small Cell Lung Cancer and Small Cell Lung Cancer), By Test (CA Test, HER2 Test, ALK Test, Angiogenesis Inhibitors, EGFR Mutation Test, and KRAS Mutation Test), By End Use (Hospitals and Clinics, Diagnostic Laboratories, and Others), and Japan Lung Cancer Diagnostics Market Insights, Industry Trend, Forecasts to 2035

Japan Lung Cancer Diagnostics Market Insights Forecasts to 2035

• The Japan Lung Cancer Diagnostics Market Size Was Estimated at USD 85.42 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 24.4% from 2025 to 2035
• The Japan Lung Cancer Diagnostics Market Size is Expected to Reach USD 943.57 Billion by 2035

Market Overview

The Japan lung cancer diagnostics market encompasses imaging technologies, biopsies, cytology, biomarker and molecular testing, and liquid biopsy technologies for the detection, characterization, and monitoring of lung cancers, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Report Coverage

This research report categorizes the market for the Japan lung cancer diagnostics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan lung cancer diagnostics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan lung cancer diagnostics market.

Driving Factors

The Japan lung cancer diagnostics market is propelled by a growing incidence of lung cancer, an aging population, and increased awareness of early detection. Advancements in imaging, molecular diagnostics, and non-invasive methods like liquid biopsy are improving diagnostic accuracy and patient adherence. Supportive government initiatives, such as national screening programs and reimbursement for advanced diagnostics, further drive adoption. Additionally, the expanding availability of targeted therapies is boosting the demand for companion diagnostics and personalized cancer profiling, contributing significantly to market growth.

Restraining Factors

The Japan lung cancer diagnostic market is under pressure with the high cost of advanced diagnostic machines, unavailability in remote areas, and unavailability of skilled practitioners. In addition, delayed regulatory approvals and resistance of patients to invasive treatments restrict the growth of the market.

Market Segmentation

The Japan lung cancer diagnostics market share is classified into type, test, and end use.

• The non-small cell lung Cancer segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan lung cancer diagnostics market is segmented by type non-small cell Lung cancer and small cell lung cancer. Among these, the non-small cell lung cancer segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to increased demand for targeted drug therapy, sophisticated imaging, and immunotherapy treatment. The most common form of non-small cell lung cancer (NSCLC) comprises adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, often found among long-term smokers.

• The EGFR mutation test segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan lung cancer diagnostics market is segmented by test into CA test, HER2 test, ALK test, angiogenesis inhibitors, EGFR mutation test, and KRAS mutation test. Among these, the EGFR mutation test segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the growing demand for EGFR mutation testing, advanced treatment options, and clinical screening for EGFR mutations. Unresolved EGFR triggers the growth of tumor cells, resulting in lung cancer at any stage. Additionally, liquid biopsy has become an easier and less invasive tool, especially in metastatic cancer settings.

• The hospitals and clinics segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan lung cancer diagnostics market is segmented by end use into hospitals and clinics, diagnostic laboratories, and others. Among these, the hospitals and clinics segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The development is spurred by the existence of hospitals and clinics that are equipped with advanced imaging technologies and improved diagnostic tools to facilitate lung cancer detection. The centers also consist of multidisciplinary panels of pathologists, radiologists, and oncologists, making them able to provide comprehensive care. They act as key centers for the provision of complex treatments such as chemotherapy and surgery.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan lung cancer diagnostics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Takeda Pharmaceutical
• Eisai
• Daiichi Sankyo
• Kyowa Kirin
• Ono Pharmaceutical
• Novartis Pharma
• Sumitomo Pharma
• Chugai Pharmaceutical
• Astellas Pharma
• AstraZeneca Pharma Japan
• Shionogi & Co.
• Otsuka Pharmaceutical
• Janssen Pharmaceutical
• Others

Recent Developments:

• In January 2021, Takeda Pharmaceutical announced approval from Japans Ministry of Health to manufacture and market ALUNBRIG® tablets (30 mg, 90 mg) as first, and second-line therapy for patients with unresectable, advanced, or recurrent ALK fusion gene-positive non-small cell lung cancer (ALK+ NSCLC).

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan lung cancer diagnostics market based on the below-mentioned segments:

Japan Lung Cancer Diagnostics Market, By Type

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Japan Lung Cancer Diagnostics Market, By Test

• CA Test
• HER2 Test
• ALK Test
• Angiogenesis Inhibitors
• EGFR Mutation Test
• KRAS Mutation Test

Japan Lung Cancer Diagnostics Market, By End Use

• Hospitals and Clinics
• Diagnostic Laboratories
• Others